Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer PatientsBenzinga • 01/27/25
Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For NowInvestors Business Daily • 01/27/25
5 Large Cap Growth Stocks With Dividend Yields Up to 8% Are Too Cheap to Ignore24/7 Wall Street • 01/27/25
Inflation Just Won't Go Away: Stick With These 5 High-Yield Dividend Giants24/7 Wall Street • 01/25/25
Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire • 01/25/25
Peri-implantitis Market Research 2025-2030: Analysis of Growth Trends and Leading Competitors, Featuring Pfizer, Cadila Pharmaceuticals, GaronitPharma, Basic Pharma Life Science, Prachi Pharmaceuticals & MoreGlobeNewsWire • 01/23/25
4 Ultra-Safe Dividend Giants That Pay More Than the 10-Year US Treasury Note24/7 Wall Street • 01/22/25
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?CNBC • 01/21/25
Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,000 in Passive Income in 2025The Motley Fool • 01/20/25
Depo-Provera Contraceptive Manufacturer Pfizer Target of Consumer Lawsuit, Brain Tumors Linked to Use, According to Law Firm FeganScottGlobeNewsWire • 01/17/25